Orestis Papasouliotis

Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Kinetics of free and ligand-bound atacicept in human serum.

Kinetics of free and ligand-bound atacicept in human serum.

Journal: Frontiers in immunology

Published: September 02, 2022

Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials.

Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials.

Journal: CPT: pharmacometrics & systems pharmacology

Published: August 15, 2022

Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.

Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.

Journal: Clinical and translational science

Published: April 22, 2022

Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants.

Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants.

Journal: Clinical and translational science

Published: April 22, 2022

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.

Journal: Cancer chemotherapy and pharmacology

Published: November 29, 2021

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.

Journal: Cancer chemotherapy and pharmacology

Published: November 26, 2021

Correction to: Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.

Correction to: Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.

Journal: European journal of drug metabolism and pharmacokinetics

Published: September 28, 2021

Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.

Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.

Journal: European journal of drug metabolism and pharmacokinetics

Published: July 11, 2021

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.

Journal: European journal of drug metabolism and pharmacokinetics

Published: September 19, 2019

Prediction of volume of distribution in humans: analysis of eight methods and their application in drug discovery.

Prediction of volume of distribution in humans: analysis of eight methods and their application in drug discovery.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: June 20, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026